Physician profile
David Robert Paulus
NPI 1366418063
$1,089.23
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $303 · 2021: $358 · 2022: $17.05.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $415.40 | 2019-2021 | |
| Novo Nordisk INC | $153.44 | 2019-2021 | |
| Glaxosmithkline, LLC. | $145.37 | 2019-2021 | |
| Abbvie INC. | $71.87 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $60.18 | 2019-2021 | |
| Pfizer INC. | $47.11 | 2019-2021 | |
| Astellas Pharma US INC | $45.42 | 2019-2021 | |
| Lilly USA, LLC | $29.68 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.70 | 2020 | |
| Allergan, INC. | $22.00 | 2019 | |
| Amgen INC. | $20.51 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.91 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.87 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $12.44 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.33 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Paulus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.